NCT06744127

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions

An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 4-period, Crossover Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fasting conditions

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	BR1015	One tablet administered alone
DRUG	BR1015-1	One tablet administered alone
DRUG	BR1015-2	One tablet administered alone

Timeline

• Start date: 2025-01-03
• Primary completion: 2025-03-14
• Completion: 2025-03-14
• First posted: 2024-12-20
• Last updated: 2025-04-09

Locations

1 site across 1 country: South Korea